Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
GALT
GALT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
GALT News
Galectin Therapeutics Q1 Earnings Report Analysis
May 15 2026
seekingalpha
Galectin Therapeutics Reports Positive Phase 2b Results for Belapectin in MASH Cirrhosis
May 11 2026
NASDAQ.COM
Galectin Therapeutics Reports FY EPS Beat Expectations
Mar 31 2026
seekingalpha
Galectin Therapeutics Under Investigation, Stock Plummets 28.9%
Jan 22 2026
PRnewswire
Galectin Therapeutics Under Investigation, Stock Plummets 28.9%
Jan 15 2026
PRnewswire
Galectin Therapeutics Faces 28.9% Stock Drop Following FDA Response on Belapectin Trial
Jan 08 2026
PRnewswire
Galectin Therapeutics Faces Securities Fraud Investigation as Stock Plummets 28.9%
Jan 06 2026
Globenewswire
Galectin Therapeutics Faces 28.9% Stock Drop Following FDA Response on Belapectin Trial
Dec 30 2025
Globenewswire
Galectin Therapeutics Shares Plunge 28.9% Following FDA Response on Belapectin Development
Dec 30 2025
Businesswire
Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway
Dec 26 2025
NASDAQ.COM
Galectin Therapeutics Receives FDA Feedback to Advance Belapectin Development
Dec 22 2025
NASDAQ.COM
Galectin Therapeutics (GALT) Price Target Raised by 83.33% to $11.22
Dec 21 2025
NASDAQ.COM
Galectin Therapeutics Receives FDA Feedback to Advance Belapectin Development
Dec 19 2025
Globenewswire
Galectin Therapeutics Receives FDA Feedback to Advance Belapectin Development
Dec 19 2025
Newsfilter
Galectin Experiences Decline Following Update on MASH Candidate Belapectin and New $10M Credit Line
Dec 19 2025
SeekingAlpha
Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
Dec 19 2025
NASDAQ.COM
Show More News
